Clinical Trial Detail

NCT ID NCT04134884
Title Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Kathy Miller
Indications

breast cancer

Therapies

ASTX727 + Talazoparib

Age Groups: senior adult

Additional content available in CKB BOOST